Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2019 | Review – Cancer Research

Expression profiles and prognostic value of miRNAs in retinoblastoma

Authors: Lara Elis Alberici Delsin, Karina Bezerra Salomao, Julia Alejandra Pezuk, Maria Sol Brassesco

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2019

Abstract

Current cure rates for retinoblastoma (RB) are very high in developed countries. Nonetheless, in less privileged places worldwide, delayed diagnosis and refusal to adhere to treatment still endure an obstacle to improve overall patient survival. Thus, the access to consistent biomarkers for diagnosis at an earlier stage may facilitate treatment and improve outcomes. Over recent years, much attention has been focused on miRNAs, key post-transcriptional regulators that when altered, largely contribute to carcinogenesis and tumor progression. Many of the ~ 2500 microRNAs described in humans have shown differential expression profiles in tumors. In this review, we summarize current data about the roles of miRNAs in RB along with their value as diagnostic/prognostic factors using electronic databases such as PubMed. We reviewed the importance of miRNA in RB biology and discussed their implications in clinic intervention. Several miRNAs have pointed out reliable diagnostic and prognostic molecular biomarkers. The emergence of targeted therapies has significantly improved cancer treatment. In the near future, the modulation of miRNAs will represent a good treatment strategy.

Acunzo M, Romano G, Wernicke D, Croce CM (2015) MicroRNA and cancer—a brief overview. Adv Biol Regul 57:1–9. https://doi.org/10.1016/j.jbior.2014.09.013 CrossRefPubMed

AlAli A, Kletke S, Gallie B, Lam W-C (2018) Retinoblastoma for pediatric ophthalmologists. Asia Pac J Ophthalmol 7:160–168. https://doi.org/10.22608/APO.201870 CrossRef

Bai Y, Bai X, Wang Z, Zhang X, Ruan C, Miao J (2011) MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 91:471–477. https://doi.org/10.1016/j.yexmp.2011.04.016 CrossRefPubMed

Berindan-Neagoe I, Monroig PDC, Pasculli B, Calin GA (2014) MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin 64:311–336. https://doi.org/10.3322/caac.21244 CrossRefPubMedPubMedCentral

Berry JL, Xu L, Murphree AL, Krishnan S, Stachelek K, Zolfaghari E, McGovern K, Lee TC, Carlsson A, Kuhn P, Kim JW, Cobrinik D, Hicks J (2017) Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. JAMA Ophthalmol 135:1221–1230. https://doi.org/10.1001/jamaophthalmol.2017.4097 CrossRefPubMedPubMedCentral

Beta M, Venkatesan N, Vasudevan M, Vetrivel U, Khetan V, Krishnakumar S (2013) Identification and insilico analysis of retinoblastoma serum microRNA profile and gene targets towards prediction of novel serum biomarkers. Bioinf Biol Insights 7:BBI.S10501. https://doi.org/10.4137/BBI.S10501 CrossRef

Beta M, Khetan V, Chatterjee N, Suganeswari G, Rishi P, Biswas J, Krishnakumar S (2014) EpCAM knockdown alters microRNA expression in retinoblastoma–functional implication of EpCAM regulated miRNA in tumor progression. PLoS One 9:e114800. https://doi.org/10.1371/journal.pone.0114800 CrossRefPubMedPubMedCentral

Busch M, Große-Kreul J, Wirtz JJ, Beier M, Stephan H, Royer-Pokora B, Metz K, Dünker N (2017) Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation. Int J Cancer 141:549–560. https://doi.org/10.1002/ijc.30768 CrossRefPubMed

Canturk S, Qaddoumi I, Khetan V, Ma Z, Furmanchuk A, Antoneli CBG, Sultan I, Kebudi R, Sharma T, Rodriguez-Galindo C, Abramson DH, Chantada GL (2010) Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol 94:1432–1436. https://doi.org/10.1136/bjo.2009.168062 CrossRefPubMed

Carvalho INSR, Reis AHO, Dos Santos ACE, Vargas FR (2017) A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. Cancer Biomark 18:313–317. https://doi.org/10.3233/CBM-160248 CrossRefPubMed

Castro-Magdonel BE, Orjuela M, Camacho J, García-Chéquer AJ, Cabrera-Muñoz L, Sadowinski-Pine S, Durán-Figueroa N, Orozco-Romero M, de J. Velázquez-Wong AC, Hernández-Ángeles A, Hernández-Galván C, Lara-Molina C, Ponce-Castañeda MV (2017) miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma. BMC Cancer 17:458. https://doi.org/10.1186/s12885-017-3421-3 CrossRefPubMedPubMedCentral

Che X, Qian Y, Li D (2018) Suppression of disheveled-axin domain containing 1 (DIXDC1) by microRNA-186 inhibits the proliferation and invasion of retinoblastoma cells. J Mol Neurosci 64:252–261. https://doi.org/10.1007/s12031-017-1017-7 CrossRefPubMed

Chen C-Z, Schaffert S, Fragoso R, Loh C (2013) Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 253:112–128. https://doi.org/10.1111/imr.12060 CrossRefPubMedPubMedCentral

Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R (2007) Retinoblastoma: review of current management. Oncologist 12:1237–1246. https://doi.org/10.1634/theoncologist.12-10-1237 CrossRefPubMed

Chung SH, Gillies M, Yam M, Wang Y, Shen W (2016) Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption. Sci Rep 6:28993. https://doi.org/10.1038/srep28993 CrossRefPubMedPubMedCentral

Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D (2011) miR-17~ 92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 25:1734–1745. https://doi.org/10.1101/gad.17027411 CrossRefPubMedPubMedCentral

Dalgard CL, Gonzalez M, deNiro JE, O’Brien JM (2009) Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. Invest Ophthalmol Vis Sci 50:4542–4551. https://doi.org/10.1167/iovs.09-3520 CrossRefPubMed

Danda R, Krishnan G, Ganapathy K, Krishnan UM, Vikas K, Elchuri S, Chatterjee N, Krishnakumar S (2013) Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy. PLoS One 8:e83398. https://doi.org/10.1371/journal.pone.0083398 CrossRefPubMedPubMedCentral

de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443–453. https://doi.org/10.1038/nrd2310 CrossRefPubMedPubMedCentral

Dimaras H, Kimani K, Dimba EAO, Gronsdahl P, White A, Chan HSL, Gallie BL (2012) Retinoblastoma. Lancet 379:1436–1446. https://doi.org/10.1016/S0140-6736(11)61137-9 CrossRefPubMed

Ding Y, Wu M, Liu J, Wu C, Huang R, Zhu R, Fei J (2014) Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. Exp Eye Res 122:1–8. https://doi.org/10.1016/j.exer.2014.02.017 CrossRefPubMed

Dismuke WM, Challa P, Navarro I, Stamer WD, Liu Y (2015) Human aqueous humor exosomes. Exp Eye Res 132:73–77. https://doi.org/10.1016/j.exer.2015.01.019 CrossRefPubMedPubMedCentral

Drewry MD, Challa P, Kuchtey JG, Navarro I, Helwa I, Hu Y, Mu H, Daniel Stamer W, Kuchtey RW, Liu Y (2018) Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma. Hum Mol Genet 27:1263–1275. https://doi.org/10.1093/hmg/ddy040 CrossRefPubMedPubMedCentral

Follert P, Cremer H, Béclin C (2014) MicroRNAs in brain development and function: a matter of flexibility and stability. Front Mol Neurosci 7:5. https://doi.org/10.3389/fnmol.2014.00005 CrossRefPubMedPubMedCentral

Friedman RC, Farh KK-H, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92–105. https://doi.org/10.1101/gr.082701.108 CrossRefPubMedPubMedCentral

Garba AO, Mousa SA (2010) Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis 2:75–83. https://doi.org/10.4137/OED.S4878 CrossRefPubMedPubMedCentral

Gill S-L, O’Neill H, McCoy RJ, Logeswaran S, O’Brien F, Stanton A, Kelly H, Duffy GP (2014) Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model. Technol Health Care 22:37–51. https://doi.org/10.3233/THC-130772 CrossRefPubMed

Gui F, Hong Z, You Z, Wu H, Zhang Y (2016) MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway. Cell Biol Int 40:1294–1302. https://doi.org/10.1002/cbin.10678 CrossRefPubMed

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73:1180–1189. https://doi.org/10.1158/0008-5472.CAN-12-2850 CrossRefPubMed

Han BW, Li ZH, Liu SF, Han HB, Dong SJ, Zou HJ, Sun RF, Jia J (2016) A comprehensive review of microRNA-related polymorphisms in gastric cancer. Genet Mol Res. https://doi.org/10.4238/gmr.15028289 CrossRefPubMed

He S-Q, Rehman H, Gong M-G, Zhao Y-Z, Huang Z-Y, Li C-H, Zhang W-G, Chen X-P (2007) Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther 6:1247–1257PubMed

Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61:112–123. https://doi.org/10.1373/clinchem.2014.222679 CrossRefPubMed

Hodgkinson CP, Kang MH, Dal-Pra S, Mirotsou M, Dzau VJ (2015) MicroRNAs and cardiac regeneration. Circ Res 116:1700–1711. https://doi.org/10.1161/CIRCRESAHA.116.304377 CrossRefPubMedPubMedCentral

Hsu S-H, Yu B, Wang X, Lu Y, Schmidt CR, Lee RJ, Lee LJ, Jacob ST, Ghoshal K (2013) Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 9:1169–1180. https://doi.org/10.1016/j.nano.2013.05.007 CrossRefPubMed

Huang JC, Babak T, Corson TW, Chua G, Khan S, Gallie BL, Hughes TR, Blencowe BJ, Frey BJ, Morris QD (2007) Using expression profiling data to identify human microRNA targets. Nat Methods 4:1045–1049. https://doi.org/10.1038/nmeth1130 CrossRefPubMed

Huang J, Yang Y, Fang F, Liu K (2018) MALAT1 modulates the autophagy of retinoblastoma cell through miR-124-mediated stx17 regulation. J Cell Biochem 119:3853–3863. https://doi.org/10.1002/jcb.26464 CrossRefPubMed

Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee M-LT, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3:e3694. https://doi.org/10.1371/journal.pone.0003694 CrossRefPubMedPubMedCentral

Hurst DR, Edmonds MD, Welch DR (2009) Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 69:7495–7498. https://doi.org/10.1158/0008-5472.CAN-09-2111 CrossRefPubMedPubMedCentral

Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694. https://doi.org/10.1056/NEJMoa1209026 CrossRefPubMed

Jia M, Wei Z, Liu P, Zhao X (2016) Silencing of ABCG2 by microRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. J Korean Med Sci 31:836–842. https://doi.org/10.3346/jkms.2016.31.6.836 CrossRefPubMedPubMedCentral

Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK (2014) Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 20:253–264. https://doi.org/10.1158/1078-0432.CCR-13-1024 CrossRefPubMed

Joseph RR, Venkatraman SS (2017) Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine (Lond) 12:683–702. https://doi.org/10.2217/nnm-2016-0379 CrossRef

Kandalam MM, Beta M, Maheswari UK, Swaminathan S, Krishnakumar S (2012) Oncogenic microRNA 17-92 cluster is regulated by epithelial cell adhesion molecule and could be a potential therapeutic target in retinoblastoma. Mol Vis 18:2279–2287PubMedPubMedCentral

Kim J, Yao F, Xiao Z, Sun Y, Ma L (2018) MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev 37:5–15. https://doi.org/10.1007/s10555-017-9712-y CrossRefPubMedPubMedCentral

Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13:e249–e258. https://doi.org/10.1016/S1470-2045(12)70073-6 CrossRefPubMed

Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, Dyer MA, Marine J-C (2010) Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ 17:633–641. https://doi.org/10.1038/cdd.2009.202 CrossRefPubMed

Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CSR, Harris AL (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675. https://doi.org/10.1111/j.1365-2141.2008.07077.x CrossRefPubMed

Levy D, Aerts I, Michon J, Lumbroso-Le Rouic L, Cellier C, Orbach D (2014) Childhood cancer: progress but prognosis still very unequal. Example of retinoblastoma and high-risk neuroblastoma. Bull Cancer 101:250–257. https://doi.org/10.1684/bdc.2014.1904 CrossRefPubMed

Li J, Xu Z-W, Wang K-H, Wang N, Li D-Q, Wang S (2014) Networks of microRNAs and genes in retinoblastomas. Asian Pac J Cancer Prev 14:6631–6636CrossRefPubMed

Li X, Yang L, Shuai T, Piao T, Wang R (2016) MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother 82:247–255. https://doi.org/10.1016/j.biopha.2016.05.003 CrossRefPubMed

Liang Y, Chen X, Liang Z (2017) MicroRNA-320 regulates autophagy in retinoblastoma by targeting hypoxia inducible factor-1α. Exp Ther Med 14:2367–2372. https://doi.org/10.3892/etm.2017.4779 CrossRefPubMedPubMedCentral

Liu K, Huang J, Xie M, Yu Y, Zhu S, Kang R, Cao L, Tang D, Duan X (2014a) MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy 10:442–452. https://doi.org/10.4161/auto.27418 CrossRefPubMedPubMedCentral

Liu S-S, Wang Y-S, Sun Y-F, Miao L-X, Wang J, Li Y-S, Liu H-Y, Liu Q-L (2014b) Plasma microRNA-320, microRNA-let-7e and microRNA-21 as novel potential biomarkers for the detection of retinoblastoma. Biomed Rep 2:424–428. https://doi.org/10.3892/br.2014.246 CrossRefPubMedPubMedCentral

Liu J, Dang L, Li D, Liang C, He X, Wu H, Qian A, Yang Z, Au DWT, Chiang MWL, Zhang B-T, Han Q, Yue KKM, Zhang H, Lv C, Pan X, Xu J, Bian Z, Shang P, Tan W, Liang Z, Guo B, Lu A, Zhang G (2015) A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials 52:148–160. https://doi.org/10.1016/j.biomaterials.2015.02.007 CrossRefPubMed

Liu H, Cao B, Zhao Y, Liang H, Hao F (2018a) Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma. Cancer Biomark. https://doi.org/10.3233/CBM-170721 CrossRefPubMedPubMedCentral

Liu S, Zhang X, Hu C, Wang Y, Xu C (2018b) miR-29a inhibits human retinoblastoma progression by targeting STAT3. Oncol Rep 39:739–746. https://doi.org/10.3892/or.2017.6144 CrossRefPubMed

Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482:347–355. https://doi.org/10.1038/nature10888 CrossRefPubMedPubMedCentral

Martin A, Jones A, Bryar PJ, Mets M, Weinstein J, Zhang G, Laurie NA (2013a) MicroRNAs-449a and – 449b exhibit tumor suppressive effects in retinoblastoma. Biochem Biophys Res Commun 440:599–603. https://doi.org/10.1016/j.bbrc.2013.09.117 CrossRefPubMed

Martin J, Bryar P, Mets M, Weinstein J, Jones A, Martin A, Vanin EF, Scholtens D, Costa FF, Soares MB, Laurie NA (2013b) Differentially expressed miRNAs in retinoblastoma. Gene 512:294–299. https://doi.org/10.1016/j.gene.2012.09.129 CrossRefPubMed

McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S (2011) MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 60:1314–1323. https://doi.org/10.2337/db10-1557 CrossRefPubMedPubMedCentral

Mirakholi M, Mahmoudi T, Heidari M (2013) MicroRNAs horizon in retinoblastoma. Acta Med Iran 51:823–829PubMed

Mitra M, Mohanty C, Harilal A, Maheswari UK, Sahoo SK, Krishnakumar S (2012) A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis 18:1361–1378PubMedPubMedCentral

Montoya V, Fan H, Bryar PJ, Weinstein JL, Mets MB, Feng G, Martin J, Martin A, Jiang H, Laurie NA (2015) Novel miRNA-31 and miRNA-200a-mediated regulation of retinoblastoma proliferation. PLoS One 10:e0138366. https://doi.org/10.1371/journal.pone.0138366 CrossRefPubMedPubMedCentral

Mortuza R, Feng B, Chakrabarti S (2014) miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 57:1037–1046. https://doi.org/10.1007/s00125-014-3197-9 CrossRefPubMed

Nair A, Thevenot P, Hu W, Tang L (2008) Nanotechnology in the treatment and detection of intraocular cancers. J Biomed Nanotechnol 4:410–418CrossRefPubMedPubMedCentral

Nguyen T, Menocal EM, Harborth J, Fruehauf JH (2008) RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 10:158–167PubMed

Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Khan A, Aitchison R, Erlich SS, PF-04523655 Study Group (2012) Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26:1099–1105. https://doi.org/10.1038/eye.2012.106 CrossRef

Nittner D, Lambertz I, Clermont F, Mestdagh P, Köhler C, Nielsen SJ, Jochemsen A, Speleman F, Vandesompele J, Dyer MA, Schramm A, Schulte JH, Marine J-C (2012) Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol 14:958–965. https://doi.org/10.1038/ncb2556 CrossRefPubMed

Papaioannou G, Mirzamohammadi F, Kobayashi T (2014) MicroRNAs involved in bone formation. Cell Mol Life Sci 71:4747–4761. https://doi.org/10.1007/s00018-014-1700-6 CrossRefPubMedPubMedCentral

Peng Y, Croce CM (2016) The role of MicroRNAs in human cancer. Signal Transduct Target Ther 1:15004. https://doi.org/10.1038/sigtrans.2015.4 CrossRefPubMedPubMedCentral

Reddy KB (2015) MicroRNA (miRNA) in cancer. Cancer Cell Int 15:38. https://doi.org/10.1186/s12935-015-0185-1 CrossRefPubMedPubMedCentral

Reis AHO, Vargas FR, Lemos B (2012) More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. Front Genet 3:284. https://doi.org/10.3389/fgene.2012.00284 CrossRefPubMedPubMedCentral

Shehata HH, Abou Ghalia AH, Elsayed EK, Ahmed Said AM, Mahmoud SS (2016) Clinical significance of high levels of survivin and transforming growth factor beta-1 proteins in aqueous humor and serum of retinoblastoma patients. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus 20:444.e1–444.e9. https://doi.org/10.1016/j.jaapos.2016.07.223 CrossRef

Shen F, Mo M-H, Chen L, An S, Tan X, Fu Y, Rezaei K, Wang Z, Zhang L, Fu SW (2014) MicroRNA-21 down-regulates Rb1 expression by targeting PDCD4 in retinoblastoma. J Cancer 5:804–812. https://doi.org/10.7150/jca.10456 CrossRefPubMedPubMedCentral

Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA (2014) Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 132:319–325. https://doi.org/10.1001/jamaophthalmol.2013.7666 CrossRefPubMed

Short BG (2008) Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 36:49–62. https://doi.org/10.1177/0192623307310955 CrossRefPubMed

Soliman SE, Dimaras H, Souka AA, Ashry MH, Gallie BL (2015) Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma. J Fr Ophtalmol 38:550–558. https://doi.org/10.1016/j.jfo.2015.03.003 CrossRefPubMed

Song D, Diao J, Yang Y, Chen Y (2017) MicroRNA-382 inhibits cell proliferation and invasion of retinoblastoma by targeting BDNF-mediated PI3K/AKT signalling pathway. Mol Med Rep 16:6428–6436. https://doi.org/10.3892/mmr.2017.7396 CrossRefPubMed

Stamatopoulos B, Van Damme M, Crompot E, Dessars B, El Housni H, Mineur P, Meuleman N, Bron D, Lagneaux L (2015) Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia. Mol Med 21:123–133. https://doi.org/10.2119/molmed.2014.00214 CrossRefPubMedPubMedCentral

Subramanian N, Kanwar JR, Kanwar RK, Krishnakumar S (2015) Blocking the maturation of oncomiRNAs using pri-miRNA-17 ~ 92 aptamer in retinoblastoma. Nucleic Acid Ther 25:47–52. https://doi.org/10.1089/nat.2014.0507 CrossRefPubMedPubMedCentral

Sun Z, Zhang A, Jiang T, Du Z, Che C, Wang F (2015) miR-145 suppressed human retinoblastoma cell proliferation and invasion by targeting ADAM19. Int J Clin Exp Pathol 8:14521–14527PubMedPubMedCentral

Tanaka Y, Tsuda S, Kunikata H, Sato J, Kokubun T, Yasuda M, Nishiguchi KM, Inada T, Nakazawa T (2014) Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system. Sci Rep 4:5089. https://doi.org/10.1038/srep05089 CrossRefPubMedPubMedCentral

Thériault BL, Dimaras H, Gallie BL, Corson TW (2014) The genomic landscape of retinoblastoma: a review. Clin Exp Ophthalmol 42:33–52. https://doi.org/10.1111/ceo.12132 CrossRefPubMed

Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM, Piskareva O, Ng CY, Lode HN, Davidoff AM, Stallings RL (2012) Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 7:e38129. https://doi.org/10.1371/journal.pone.0038129 CrossRefPubMedPubMedCentral

To K-H, Pajovic S, Gallie BL, Thériault BL (2012) Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development. BMC Cancer 12:69. https://doi.org/10.1186/1471-2407-12-69 CrossRefPubMedPubMedCentral

Traoré F, Sylla F, Togo B, Kamaté B, Diabaté K, Diakité AA, Diall H, Dicko F, Sylla M, Bey P, Desjardins L, Gagnepain-Lacheteau A, Coze C, Harif M, Doz F (2018) Treatment of retinoblastoma in Sub-Saharan Africa: experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali. Pediatr Blood Cancer 65:e27101. https://doi.org/10.1002/pbc.27101 CrossRefPubMed

Tsang JS, Ebert MS, van Oudenaarden A (2010) Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 38:140–153. https://doi.org/10.1016/j.molcel.2010.03.007 CrossRefPubMedPubMedCentral

Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131–1135. https://doi.org/10.1016/j.addr.2006.07.027 CrossRefPubMed

Venkatesan N, Deepa PR, Khetan V, Krishnakumar S (2015) Computational and in vitro investigation of miRNA-gene regulations in retinoblastoma pathogenesis: miRNA mimics strategy. Bioinf Biol Insights 9:BBI.S21742. https://doi.org/10.4137/BBI.S21742 CrossRef

Wang S, Olson EN (2009) AngiomiRs—key regulators of angiogenesis. Curr Opin Genet Dev 19:205–211. https://doi.org/10.1016/j.gde.2009.04.002 CrossRefPubMedPubMedCentral

Wang J, Wang X, Wu G, Hou D, Hu Q (2013) MiR-365b-3p, down-regulated in retinoblastoma, regulates cell cycle progression and apoptosis of human retinoblastoma cells by targeting PAX6. FEBS Lett 587:1779–1786. https://doi.org/10.1016/j.febslet.2013.04.029 CrossRefPubMed

Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q, Zhou Z, Zhang F, Zhang R, Wu Y, Sheng W, Zeng Y (2015) Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthc Mater 4:281–290. https://doi.org/10.1002/adhm.201400222 CrossRefPubMed

Wang Y, Li X, Tao B (2016) Improving classification of mature microRNA by solving class imbalance problem. Sci Rep 6:25941. https://doi.org/10.1038/srep25941 CrossRefPubMedPubMedCentral

Wang Z, Yao Y-J, Zheng F, Guan Z, Zhang L, Dong N, Qin W-J (2017) Mir-138-5p acts as a tumor suppressor by targeting pyruvate dehydrogenase kinase 1 in human retinoblastoma. Eur Rev Med Pharmacol Sci 21:5624–5629PubMed

Wecker T, Hoffmeier K, Plötner A, Grüning BA, Horres R, Backofen R, Reinhard T, Schlunck G (2016) MicroRNA profiling in aqueous humor of individual human eyes by next-generation sequencing. Invest Ophthalmol Vis Sci 57:1706–1713. https://doi.org/10.1167/iovs.15-17828 CrossRefPubMed

Wei D, Miao Y, Yu L, Wang D, Wang Y (2018) Downregulation of microRNA-198 suppresses cell proliferation and invasion in retinoblastoma by directly targeting PTEN. Mol Med Rep 18:595–602. https://doi.org/10.3892/mmr.2018.8979 CrossRefPubMed

Wu J, Bao J, Kim M, Yuan S, Tang C, Zheng H, Mastick GS, Xu C, Yan W (2014) Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis. Proc Natl Acad Sci USA 111:E2851–E2857. https://doi.org/10.1073/pnas.1407777111 CrossRefPubMedPubMedCentral

Wu K, He J, Pu W, Peng Y (2018a) The role of exportin-5 in microRNA biogenesis and cancer. Genom Proteom Bioinf 16:120–126. https://doi.org/10.1016/j.gpb.2017.09.004 CrossRef

Wu S, Ai N, Liu Q, Zhang J (2018b) MicroRNA-448 inhibits the progression of retinoblastoma by directly targeting ROCK1 and regulating PI3K/AKT signalling pathway. Oncol Rep 39:2402–2412. https://doi.org/10.3892/or.2018.6302 CrossRefPubMed

Wu L, Chen Z, Xing Y (2018c) MiR-506-3p inhibits cell proliferation, induces cell cycle arrest and apoptosis in retinoblastoma by directly targeting NEK6. Cell Biol Int. https://doi.org/10.1002/cbin.11041 CrossRefPubMed

Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G, Ge S, Fan X (2011) Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol 38:1385–1393. https://doi.org/10.3892/ijo.2011.961 CrossRefPubMed

Xu X, Ge S, Jia R, Zhou Y, Song X, Zhang H, Fan X (2015) Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6. Oncol Rep 33:2789–2796. https://doi.org/10.3892/or.2015.3900 CrossRefPubMed

Yang Y, Mei Q (2015) miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression. Mol Vis 21:1307–1317CrossRefPubMedPubMedCentral

Yang G, Fu Y, Zhang L, Lu X, Li Q (2017) miR106b regulates retinoblastoma Y79 cells through Runx3. Oncol Rep 38:3039–3043. https://doi.org/10.3892/or.2017.5931 CrossRefPubMed

Yang L, Wei N, Wang L, Wang X, Liu Q-H (2018) miR-498 promotes cell proliferation and inhibits cell apoptosis in retinoblastoma by directly targeting CCPG1. Childs Nerv Syst 34:417–422. https://doi.org/10.1007/s00381-017-3622-8 CrossRefPubMed

Zhang Y, Xue C, Zhu X, Zhu X, Xian H, Huang Z (2016) Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation. Cell Signal 28:850–860. https://doi.org/10.1016/j.cellsig.2016.04.002 CrossRefPubMed

Zhang Y, Zhu X, Zhu X, Wu Y, Liu Y, Yao B, Huang Z (2017) MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5. Tumour Biol 39:1010428317691674. https://doi.org/10.1177/1010428317691674 CrossRefPubMed

Zhang J, He J, Zhang L (2018a) The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling. Biomed Pharmacother 106:35–42. https://doi.org/10.1016/j.biopha.2018.06.099 CrossRefPubMed

Zhang M, Li Q, Pan Y, Wang H, Liu G, Yin H (2018b) MicroRNA-655 attenuates the malignant biological behaviours of retinoblastoma cells by directly targeting PAX6 and suppressing the ERK and p38 MAPK signalling pathways. Oncol Rep 39:2040–2050. https://doi.org/10.3892/or.2018.6264 CrossRefPubMed

Zhang Y, Wang X, Zhao Y (2018c) MicroRNA-874 prohibits the proliferation and invasion of retinoblastoma cells by directly targeting metadherin. Mol Med Rep. https://doi.org/10.3892/mmr.2018.9295 CrossRefPubMedPubMedCentral

Zhao J-J, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin J-Y, Ma X (2009) Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 25:13–20. https://doi.org/10.1007/s00381-008-0701-x CrossRefPubMed

Title: Expression profiles and prognostic value of miRNAs in retinoblastoma
Authors: Lara Elis Alberici Delsin
Karina Bezerra Salomao
Julia Alejandra Pezuk
Maria Sol Brassesco
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2773-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer

Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression

Combination of gold nanoparticles with low-LET irradiation: an approach to enhance DNA DSB induction in HT29 colorectal cancer stem-like cells

Surgical staging in endometrial cancer

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage